Affinity Asset Advisors LLC Boosts Stock Position in ProQR Therapeutics N.V. $PRQR

Key Points

• Affinity Asset Advisors LLC increased its holdings in ProQR Therapeutics by 16.3%, owning approximately 3.12% of the company after acquiring additional shares in the 1st quarter.
• Multiple institutional investors have significantly boosted their stakes in ProQR Therapeutics, with Northern Trust Corp increasing its holdings by 2,550.1% and Millennium Management by 1,864.4%.
• ProQR Therapeutics has a consensus rating of Buy with an average target price of $8.00, despite reporting a quarterly loss and missing revenue expectations.

Affinity Asset Advisors LLC boosted its stake in shares of ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) by 16.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,284,512 shares of the biopharmaceutical company's stock after purchasing an additional 459,512 shares during the quarter. Affinity Asset Advisors LLC owned about 3.12% of ProQR Therapeutics worth $4,368,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in PRQR. Jane Street Group LLC bought a new stake in ProQR Therapeutics during the fourth quarter valued at about $30,000. Invesco Ltd. bought a new stake in ProQR Therapeutics during the fourth quarter valued at about $32,000. Alpine Global Management LLC bought a new stake in ProQR Therapeutics during the fourth quarter valued at about $39,000. Two Sigma Securities LLC bought a new stake in ProQR Therapeutics during the fourth quarter valued at about $40,000. Finally, Vontobel Holding Ltd. bought a new stake in ProQR Therapeutics during the first quarter valued at about $48,000. Institutional investors own 32.65% of the company's stock.

Analyst Ratings Changes

PRQR has been the subject of several recent analyst reports. JMP Securities reissued a "market outperform" rating and issued a $8.00 price target on shares of ProQR Therapeutics in a report on Friday, June 27th. Evercore ISI reissued an "outperform" rating on shares of ProQR Therapeutics in a report on Friday, July 11th. Chardan Capital reissued a "buy" rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Friday, August 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $8.00 target price on shares of ProQR Therapeutics in a report on Friday, June 27th. Finally, Oppenheimer decreased their target price on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $8.00.

ProQR Therapeutics Price Performance

PRQR stock traded up $0.06 during trading on Friday, hitting $2.25. 152,458 shares of the company traded hands, compared to its average volume of 318,862. The stock's 50-day simple moving average is $2.16 and its 200 day simple moving average is $1.87. The company has a market cap of $236.72 million, a PE ratio of -4.89 and a beta of 0.43. ProQR Therapeutics N.V. has a 1 year low of $1.07 and a 1 year high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). The company had revenue of $4.33 million for the quarter, compared to analysts' expectations of $5.01 million. ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%. Research analysts expect that ProQR Therapeutics N.V. will post -0.31 earnings per share for the current year.

ProQR Therapeutics Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).